Changeflow GovPing Courts & Legal DOJ Resolves Foreign Bribery Probe with Balt SA...
Priority review Enforcement Added Final

DOJ Resolves Foreign Bribery Probe with Balt SAS; Executives Indicted

Favicon for www.justice.gov DOJ News
Filed
Detected
Email

Summary

The Department of Justice announced a resolution with Balt SAS, a French medical device company, for a foreign bribery scheme, declining prosecution due to voluntary self-disclosure and cooperation, resulting in a $1.2 million disgorgement. Separately, two individuals, David Ferrera and Marc Tilman, were indicted for their alleged roles in the scheme.

Published by DOJ on justice.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The Department of Justice has resolved a foreign bribery investigation with Balt SAS, a French medical device company, under its Corporate Enforcement Policy. Due to Balt's voluntary self-disclosure, full cooperation, and remediation, the DOJ declined to prosecute the company, which will pay approximately $1.2 million in disgorgement. This resolution was coordinated with the French Parquet National Financier (PNF).

In parallel, a federal grand jury indicted two individuals, David Ferrera (a former executive at Balt's U.S. subsidiary) and Marc Tilman (a consultant), for allegedly paying bribes to a French hospital official between 2017 and 2023 to secure purchases of medical devices. The indictment alleges the use of sham consulting agreements and personal email accounts to conceal the scheme. This action highlights the DOJ's commitment to prosecuting individuals involved in corrupt foreign practices, even when corporate resolutions are reached.

What to do next

  1. Review FCPA compliance policies and procedures.
  2. Assess existing controls for foreign payments and consulting agreements.
  3. Ensure robust reporting mechanisms for potential misconduct.

Penalties

Balt SAS agreed to pay approximately $1.2 million in disgorgement.

Archived snapshot

Mar 20, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

MENU News

Archived Press Releases

Archived News

Press Release

Justice Department Resolves Foreign Bribery Investigation with Balt SAS; Healthcare Executive and Sales Consultant Indicted in Alleged Years-Long Foreign Bribery Scheme

Thursday, March 19, 2026

Share For Immediate Release Office of Public Affairs The Department of Justice announced today a resolution of a foreign bribery investigation into Balt SAS (Balt), a medical device company headquartered in France, relating to an alleged scheme to pay bribes to a physician who served in a senior role at a state-owned public hospital in France (the Official), in violation of the Foreign Corrupt Practices Act (FCPA). Pursuant to the resolution, under Part I of the Justice Department’s Corporate Enforcement and Voluntary Self-Disclosure Policy (CEP), because Balt voluntarily self-disclosed the misconduct, fully cooperated with the Department’s investigation, and timely and appropriately remediated the wrongdoing, the Department declined to prosecute Balt, which agreed to pay approximately $1.2 million in disgorgement. In addition to the Department’s enforcement action, the Parquet National Financier (PNF) in France entered into a coordinated resolution with Balt following a court hearing earlier today.

Separately, a federal grand jury in the Central District of California returned an indictment on March 4, 2026, charging two businessmen for their roles in the alleged years-long criminal scheme. David Ferrera, 58, of Coto de Caza, California, worked as an executive at Balt’s U.S. subsidiary. Marc Tilman, 68, of Belgium, was hired by Balt’s U.S. subsidiary as a consultant. According to court documents, between approximately 2017 and continuing into 2023, Ferrera, Tilman, and others allegedly paid bribes to the Official in order for the Official to cause the hospital to purchase medical devices — specifically, endovascular embolization coils and ancillary products — from Balt. As alleged, Ferrera caused Balt to make corrupt payments — disguised as purported consulting fees and bonuses — to Tilman, knowing that Tilman would pay a portion of those funds to the Official as bribes. To conceal the scheme, the co-conspirators allegedly used sham consulting agreements, fake invoices, and personal email accounts.

“Today’s resolution – the first ever under the Department-wide Corporate Enforcement Policy – demonstrates the value of voluntarily self-reporting wrongdoing to the Department of Justice,” said Assistant Attorney General A. Tysen Duva of the Justice Department’s Criminal Division. “This corporate resolution, which is coordinated with our foreign partners at the PNF in France, credits Balt’s self-report to the Department as well as its full cooperation and timely remediation. Our related indictment of two individuals associated with Balt demonstrates the Criminal Division’s unwavering pursuit of culpable individuals that engage in corrupt conduct.”

“Ferrera and Tilman allegedly conspired to pay bribes to a French physician, who in turn caused a hospital in France to purchase medical devices from their company,” said Assistant Director in Charge Darren Cox of the FBI Washington Field Office. “Let their indictment serve as a testament to the FBI's long reach. When corruption extends beyond our borders, the FBI works with our international partners to bring individuals to justice.”

The Department declined prosecution of Balt based on an assessment of the factors set forth in the Department-wide CEP and the Principles of Federal Prosecution of Business Organizations (Justice Manual 9-28.300), including, but not limited to: (1) Balt’s timely and voluntary self-disclosure of the misconduct, which was identified during an internal investigation that was ongoing at the time of the disclosure; (2) Balt’s full and proactive cooperation in this matter (including its provision of all known relevant facts of the misconduct and information regarding the individuals involved) and its agreement to continue to cooperate with any ongoing Department investigations and any prosecutions that have resulted or might result in the future; (3) the nature and seriousness of the offense; (4) Balt’s timely and appropriate remediation, including disciplinary action against relevant personnel, termination of the business relationships that gave rise to the misconduct, tailored compliance training for Balt senior management, and improvements to its compliance program and internal controls; (5) the absence of aggravating circumstances that, when weighed against Balt’s voluntary self-disclosure, cooperation, and remediation, would warrant a disposition other than a resolution under Part I of the CEP; (6) Balt’s acceptance of responsibility for the criminal conduct and  entry into a parallel resolution with authorities in France, which will also include corporate compliance requirements imposed under the French system; and (7) that Balt agrees to disgorge the amount of its ill-gotten gains.

Ferrera and Tilman are each charged with one count of conspiracy to violate the FCPA, two counts of violating the FCPA, one count of conspiracy to commit money laundering, and two counts of money laundering. If convicted, each faces a maximum penalty of five years in prison for each of the bribery conspiracy and bribery charges and 20 years in prison for each of the money laundering conspiracy and money laundering charges.

The FBI Washington Field Office is investigating the case.

Fraud Section Trial Attorney Patrick Brown and Senior Counsel Peter Cooch of the Criminal Division are prosecuting the case. The Justice Department’s Office of International Affairs provided significant assistance.

The Fraud Section is responsible for investigating and prosecuting FCPA and Foreign Extortion Prevention Act (FEPA) matters. Additional information about the Justice Department’s FCPA and FEPA enforcement efforts can be found at www.justice.gov/criminal/fraud/fcpa.

An indictment is merely an allegation. All defendants are presumed innocent until proven guilty beyond a reasonable doubt in a court of law.

Updated March 19, 2026 Topic Financial Fraud Components Criminal Division Criminal - Criminal Fraud Section Criminal - Office of International Affairs Federal Bureau of Investigation (FBI) Press Release Number: 26-270

Related Content

Press Release Swiss Businessman Extradited to the United States Pleads Guilty to International Securities Fraud Scheme A Swiss executive pleaded guilty today to participating in a multimillion-dollar securities fraud scheme after living abroad as a fugitive for nearly 11 years.

March 10, 2026

Press Release Pennsylvania Brothers Convicted of Decades Long Racketeering Conspiracy Three individuals were convicted today at trial in connection with a racketeering conspiracy encompassing multiple fraud schemes, including visa fraud to employ foreign workers unlawfully, soliciting salary kickbacks from the...

March 9, 2026

Press Release U.S. Department of Justice Announces Distribution of over $15.5 Million to Compensate Victims of Massive Global Securities Fraud Scheme The U.S. Department of Justice announced today that the Roger Knox Remission Fund has begun distributing more than $12.4 million in funds forfeited to the United States from Roger Knox...

March 2, 2026

Named provisions

Corporate Enforcement and Voluntary Self-Disclosure Policy

Get daily alerts for DOJ News

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from DOJ.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
DOJ
Filed
March 19th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
DOJ News Release

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Foreign Bribery Sales
Geographic scope
United States US

Taxonomy

Primary area
Anti-Money Laundering
Operational domain
Compliance
Topics
Foreign Corrupt Practices Act Corporate Enforcement Policy

Get alerts for this source

We'll email you when DOJ News publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!